Interdisciplinary Medicine编委， Nature Metabolism, Cell Metabolism, Advanced Science 等多个国际高水平期刊审稿人。

国家海外高层次引进人才，四川省杰出青年科学基金和四川大学“百人计划”获得者，免疫检验研究室副主任。四川省“天府EM计划”及成都市“RP计划”专项人才。长期致力于代谢性疾病、肿瘤代谢、衰老、肿瘤免疫和靶向治疗的前沿基础研究，围绕“衰老与代谢性疾病”“代谢重编程与肿瘤发生”“代谢与肿瘤免疫逃逸”“肠道微生物与肿瘤发生”“肿瘤靶向治疗和免疫治疗”等重大科学问题，以第一作者/通讯作者(含共同)在Nature（2025）、Cell Metabolism、 Molecular Cell、PNAS、Cell Reports、Hepatology (2篇)、Cancer Research、Molecular Cancer和Cell Death & Differentiation (2篇) 等高水平一区top期刊发表论文12篇。主持国家自然科学基金重大研究计划、国家自然科学基金面上项目、青年基金项目和四川省杰青等项目多项。

第一作者和通讯作者论文

1. Gu L#, *, Zhu Y#, *, Nandi SP, Lee M, Watari K, Bareng B, Ohira M, Liu Y, Sakane S, Carlessi R, Sauceda C, Dhar D, Ganguly S, Hosseini M, Teneche M, Adams P, Gonzalez D, Kisseleva T, Tirnitz-Parker JEE, Simon MC, Alexandrov LB, Karin M*. FBP1 Controls Liver Cancer Evolution from Senescent MASH Hepatocytes. Nature, 2025;637(8045):461-469. *Co-corresponding author. (第一作者兼共同通讯作者) (影响因子：64.80) Nature Reviews gastroenterology &hepatology以“MASH-induced senescence and liver cancer”为题对本文进行了亮点介绍。

2. Gu L#, Zhu Y#, Watari K, Lee M, Liu J, Perez S, Thai M, Mayfied JE, Zhang B, Rocha KC, Li F, Kim LC, Jones AC, Liu X, Newton AC, Lee JH, Kisseleva T, Ying W, Saltiel, AR, Simon MC, Karin M*. FBP1 is a nonenzymatic safety valve that curtails AKT activation to prevent insulin hyperresponsiveness. Cell Metabolism, 2023;35(6):1009-1021.( 影响因子：31.373) Nature Reviews Endocrinology以“Nonenzymatic prevention of insulin hyperresponsiveness by FBP1”为题对本文进行了亮点介绍。

3. Gu L#, Zhu Y#, Lee M, Nguyen A, Ryujin N, Huang J, Chamseddine S, Xiao L, Mohamed Y, Kaseb A, Karin M*, Shalapour S*. Angiotensin II receptor inhibition ameliorates liver fibrosis and enhances hepatocellular carcinoma infiltration by effector T cells. Proceedings of the National Academy of Sciences, 2023; 120(19):e2300706120. (影响因子：12.779)

4. Gu L#, Zhu Y#, Lin X, Lu B, Zhou X, Zhou F, Zhao Q, Prochownik EV, Li Y. The IKKβ-USP30-ACLY Axis Controls Lipogenesis and Tumorigenesis. Hepatology, 2021; 1:160-174. #Co-first author. (影响因子：17.298)

5. Yang S, Hu C, Chen X, Tang Y, Li J, Yang H, Yang Y, Ying B*, Xiao X*, Li S*, Gu L*, Zhu Y*. Crosstalk between metabolism and cell death in tumorigenesis. Molecular Cancer, 2024; 23: 71. *Corresponding author. (影响因子: 37.30)

6. Zhu Y#, Gu L#, Lin X, Liu C, Lu B, Cui K, Zhou F, Zhao Q, Prochownik EV, Fan C, Li Y. Dynamic Regulation of ME1 Phosphorylation and Acetylation Affects Lipid Metabolism and Colorectal Tumorigenesis. Molecular Cell, 2020; 1: 138-149. #Co-first author.  (影响因子：19.329)

7. Gu L#, Zhu Y#, Lin X, Li Y, Cui K, Prochownik EV, Li Y. Amplification of Glyceronephosphate O-Acyltransferase and Recruitment of USP30 Stabilize DRP1 to Promote Hepatocarcinogenesis. Cancer Research, 2018; 20: 5808-5819. (影响因子：13.312)

8. Zhu Y#, *, Gu L#, Lin X, Zhou X, Lu B, Liu C, Li Y, Prochownik EV, Karin M, Li Y*. P53 deficiency affects cholesterol esterification to exacerbate hepatocarcinogenesis. Hepatology, 2023;77(5):1499-1511. #Co-first author. (影响因子：17.298) 同期Hepatology 以“P53 Is Watching Your Cholesterol”为题对本文进行亮点推荐。

9. Zhu Y, Wei D, Karin M*, Gu L*. The FBP1-TP53-NRF2 metabolic switch in metabolic dysfunction-associated steatohepatitis-hepatocellular carcinoma progression and senescence reversal. Clin Transl Med. 2025;15(4):e70293  *Co-corresponding author. *Co-corresponding author. (影响因子：7.9)

10. Gu L*, Zhu Y, Lin X, Tan X, Lu B, Li Y*. Stabilization of FASN by ACAT1-mediated GNPAT acetylation promotes lipid metabolism and hepatocarcinogenesis. Oncogene, 2020; 11: 2437-2449. *Co-corresponding author. (影响因子：8.756) (第一作者兼共同通讯作者)

11. Zhu Y#, *, Gu L#, Lin X, Zhou X, Lu B, Cheng L, Lei C, Zhou F, Zhao Q, Prochownik EV, Li Y*. USP19 exacerbates lipogenesis and colorectal carcinogenesis by stabilizing ME1. Cell Reports, 2021; 37: 110174. #Co-first author. (影响因子：9.995)

12. Zhu Y#, Gu L#, Li Y, Lin X, Shen H, Chen L, Zhong B, Li Y. Ablation of MicroRNA-148a affects colitis and colitis-associated tumorigenesis in mice. Cell Death & Differentiation, 2017; 24：2199-2209. #Co-first author. (影响因子：12.073)